- 1School of Life Sciences, Jiangsu University, Zhenjiang, China
- 2School of Food and Biological Engineering, Jiangsu University, Zhenjiang, China
Branched-chain amino acid aminotransferases, widely present in natural organisms, catalyze bidirectional amino transfer between branched-chain amino acids and branched-chain α-ketoacids in cells. Branched-chain amino acid aminotransferases play an important role in the metabolism of branched-chain amino acids. In this paper, the interspecific evolution and biological characteristics of branched-chain amino acid aminotransferases are introduced, the related research of branched-chain amino acid aminotransferases in animals, plants, microorganisms and humans is summarized and the molecular mechanism of branched-chain amino acid aminotransferase is analyzed. It has been found that branched-chain amino acid metabolism disorders are closely related to various diseases in humans and animals and plants, such as diabetes, cardiovascular diseases, brain diseases, neurological diseases and cancer. In particular, branched-chain amino acid aminotransferases play an important role in the development of various tumors. Branched-chain amino acid aminotransferases have been used as potential targets for various cancers. This article reviews the research on branched-chain amino acid aminotransferases, aiming to provide a reference for clinical research on targeted therapy for various diseases and different cancers.
1 Introduction
Branched-chain amino acid aminotransferases (BCATs) play a vital role in the metabolism of branched-chain amino acids (BCAAs) and are an important regulator. BCAT is the only enzyme common to BCAA biosynthesis and degradation and BCAT activity affects BCAA homeostasis. BCAAs include valine (Val), leucine (Leu), and isoleucine (Ile) (Shou et al., 2019). Humans cannot synthesize branched-chain amino acids, and they need to be ingested from the outside through diet. BCAAs play an important role, with leucine known for its vital role in protein anabolism by activating the mammalian target of rapamycin (mTOR) signaling pathway (Dimou et al., 2022). BCAAs play an important role in skeletal muscle as an energy source. During exercise, BCAAs, especially leucine, transaminated in skeletal muscle, producing acetyl-CoA to the Krebs cycle. This amino group can be transamimoniated to alanine, which is produced in the liver through the glucose-alanine cycle, producing excess liver glycogen (de Campos-Ferraz et al., 2014). In addition to the effects on energy expenditure in exercise as well as muscle damage, proper BCAA supplementation may have relatively beneficial effects on many pathologies, such as liver and kidney disease (Dimou et al., 2022) and muscle wasting disorders (Cano et al., 2006). It can also act as an important nutritional signal and metabolic regulator and has a role in glucose homeostasis, the nervous system, and the immune response (Holeček, 2018). BCAAs metabolism differs from other essential amino acid metabolism. BCAAs are first transported in extrahepatic tissues and need to be shuttled between organs or tissues for complete catabolism (Ananieva and Wilkinson, 2018). The first step in human BCAA catabolism is the reversible transamination process, BCAAs transfer amino groups to α-ketoglutarate (α-KG) to produce 2-ketoisocaproate (KIC), 2-keto-3-methylvalerate (KMV), 2-ketoisovalerate (KIV), and glutamic acid (Glu). Since BCAT catalyzes the reaction is reversible, the active center of BCAT is the recognition of acidic amino acids (Glu) as well as hydrophobic amino acids (BCAAs), a dual substrate recognition mechanism (Goto et al., 2003). BCAT activity is high in skeletal muscle (Shimomura et al., 2006). Therefore, it is thought that this step is mainly performed in skeletal muscle. The second step is catalyzed by Branched chain α-ketoacid dehydrogenase complex, it is located in the inner mitochondrial membrane and irreversibly oxidizes α-ketoacids to produce isovaleryl-CoA, 3-methylbutyryl- CoA, isobutyryl-CoA, CO2 and NADH. BCKD kinase (BCKDK) phosphorylates BCKD leading to its inactivation, protein phosphatase 2Cm (PP2Cm) dephosphorylates BCKD leading to its activation, and the activity of BCKDC is strictly regulated to maintain BCAA homeostasis in vivo (Islam et al., 2010). The third step of BCAA catabolism is the production of acetyl-CoA and succinyl-CoA into the Krebs cycle, which produces ATP, as shown in Figure 1. In contrast to other tissues, the BCAA degradation process occurs mainly in muscles and the liver. BCAA catabolism involves two initial enzymatic reactions common to all BCAAs, and the intake of a single BCAA affects the catabolism of all three BCAAs (Hutson et al., 2005).
BCAT participates in metabolic reactions, is closely related to some animal and plant diseases, and participates in plant defense responses and fruit ripening. BCAT is also closely related to human conditions, such as diabetes, neurological diseases, etc. Decreased glycolysis in diabetic patients leads to decreased aminoreceptors (α-ketoglutarate), and decreased transamination of branched-chain amino acids leads to accumulation of branched-chain amino acids (Holeček, 2020). Studies have found a positive correlation between severity and commonplace BCAT levels in Alzheimer’s patients (Hudd et al., 2019), and demonstrates a high expression in many types of tumors, having an obvious correlation with the value-added invasion and prognosis of tumor cells. Earlier studies have focused on characterizing the structure of BCAT, analyzing the relationships between enzymes and substrates and the biological properties of enzymes, and cloning expression purification, which will facilitate the industrial production of enantiomeric chiral amino acids by aminotransferases. With the rapid development of scientific and technological methods, more attention is paid to research at the molecular level, the expression signaling pathway of the BCAT gene, and the relationship between BCAT and disease. The latter is analyzed more comprehensively and specifically by combining the genomic transcriptome and metabolomics.
2 Evolution and biological characteristics of branched-chain amino acid aminotransferases
BCAA aminotransferases are classified as folded type IV aminotransferases, a pyridoxal 5′-phosphate (PLP)-dependent enzyme (Schiroli and Peracchi, 2015). They play a vital role in living organisms. With the rapid development of genome sequencing technology, the protein gene sequences are becoming clearer. The BCAT gene sequences of different species can be obtained, and the differences among species can be understood at the molecular level. The NCBI website has recorded the genetic sequences of branched-chain amino acid aminotransferases from more than 300,000 species, and a variety of BCAT protein sequences have been described.
For most eukaryotes, including humans, there are two subtypes of branched-chain amino acid aminotransferases: BCAT1 and BCAT2 (Papathanassiu et al., 2017). It has long been thought that these two enzymes have similar physiological functions in cells and drive the same transamination response. But studies have gradually revealed differences in their physiological functions and regulatory mechanisms (Toyokawa et al., 2021). BCAT1 encodes a cytoplasmic protein expressed primarily in the brain that provides nitrogen for cerebral glutamate synthesis (Wang et al., 2015) and is secondarily expressed in embryonic tissue, the ovaries, the placenta, and neurons of the peripheral nervous system, regulating mammalian target of rapamycin complex 1 (mTORC1) signaling and glycolytic metabolism in CD4+ T cells (Ananieva et al., 2014). BCAT2 encodes a mitochondrial protein commonly expressed in almost all organs (Knerr et al., 2019).
BCATs have been identified in plants such as Arabidopsis, rice, wheat, rape, tomato, etc., which are mostly cash crops. As a representative model plant, Arabidopsis thaliana has been extensively studied in many aspects, and six BCAT subtypes have been identified in Arabidopsis (Diebold et al., 2002). Six BCAT genes (SIBCAT) were identified in tomatoes (Maloney et al., 2010). SlBCAT1, SlBCAT2, SlBCAT3, and SlBCAT4 are expressed in a variety of plant tissues. While SlBCAT5 and SlBCAT6 are undetectable, six isoforms are active in both forward (BCAA synthesis) and reverse (branched-chain ketoacid synthesis) reactions. Detailed BCAT information is shown in Table 1. Different subtypes of BCAT perform different functions in different subunits of cells, and the enzyme kinetic characteristics are different (Km values are shown in Table 2), the smaller the Km value, the greater the enzyme affinity for substrates, which verifies that mitochondrial SlBCAT1 and SlBCAT2 play a role in BCAA catabolism, while chloroplasts SlBCAT3 and SlBCAT4 play a role in BCAA synthesis (Maloney et al., 2010). Comparing the kinetic parameters of enzymes in different species or different subtypes of the same species can help better understand the function of enzymes and the differences in function.
The BCATs in Saccharomyces cerevisiae is encoded by two genes, BCAT1 and BCAT2 (Eden et al., 1996). BCAT1 is mainly in mitochondria, while BCAT2 is in the cytoplasm (Kispal et al., 1996). Six genes encoding BCAA aminotransferase were identified in Aspergillus nidularis, a filamentous fungus. Six BAT isoenzymes as well as coding genes were identified by using BLAST analysis (Shimizu et al., 2010); details are shown in Table 1. The S. cerevisiae BAT protein sequence shows different degrees of similarity compared with the six BAT enzymes of A. nidularis (Steyer et al., 2021). Two BCAA aminotransferases (BCATa and BCATb) play a role in Ile and Val biosynthesis and play a major role in Leu biosynthesis. The gene encoding BCAT in Mycobacterium tuberculosis is a member of the subfamily IIIa of transaminases. The M. tuberculosis IlvE monomer consists of two domains that interact to form the active site, and the conserved N-terminal Phe30 residue can confer additional substrate selectivity (Tremblay and Blanchard, 2009). D- and L-cycloserine can inactivate branched-chain aminotransferases of M. tuberculosis and inhibit multiple PLP-dependent enzymes (Amorim Franco et al., 2017). BCAT catalyzes the formation of methionine from α-keto-γ-methiolbutyrate (Venos et al., 2004), and all mycobacterial BCAT sequences were found to be identical to M. tuberculosis sequences except for those in M. bovum (Venos et al., 2004). BCAT affects the growth and survival of Mycobacterium tuberculosis, so it may be a candidate gene for the development of inhibitors (Amorim Franco et al., 2016). Staphylococcus can also catalyze the transamination of methionine to a certain extent (Madsen et al., 2002).
In order to understand the differences of BCAT in different species, the BCAT of different species was analyzed by primary structure, and the conservatism of BCAT sequences of animals, plants, and microorganisms was analyzed. A multi-sequence alignment analysis of Homo sapiens, Escherichia coli, Mycobacterium tuberculosis, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Hordeum vulgare, Darnio rerio, Streptococcus pneumoniae BCAT was conducted, and the results are shown in Figure 2. Understanding the differences in the primary structure of BCAT has a significant impact on enzyme function. BCAT is a PLP-dependent enzyme that binds to conserved catalytic lysine residues (as shown in Figure 2, the black box indicates the conserved catalytic lysine residues of BCATs). In Saccharomyces cerevisiae BCATs, amino acid substitution of lysine at position 219 in BCAT1 and position 202 in BCAT2 has been reported to lose its enzymatic catalytic activity (Kingsbury et al., 2015). More importantly, the amino acid substitution of lysine residues catalyzed by BCAT2 (K202H and K202M) not only led to the loss of catalytic activity, but also yeast cells expressed these dysfunctional Bat2 proteins under multiple stress conditions (e.g., pH, caffeine.), showing different growth phenotypes compared to wild-type cells (Espinosa-Cantú et al., 2018). Therefore, understanding the primary structure of the enzyme will give a clearer understanding of the function of the enzyme.
FIGURE 2. Multiple alignment of Homo sapiens, Escherichia coli, Mycobacterium tuberculosis, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Hordeum vulgare, Darnio rerio, Streptococcus pneumoniae BCAT amino acid sequence. A black box indicates the conserved-catalytic lysine residues of BCATs. hBCAT, ecBCAT, mtBCAT, scBCAT, sp1BCAT, hvBCAT, drBCAT and sp2BCAT indicate BCATs derived from Homo sapiens, Escherichia coli, Mycobacterium tuberculosis, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Hordeum vulgare, Darnio rerio, Streptococcus pneumoniae, respectively.
Finding homologous sequences and analyzing their functions is one way to understand the general use of proteins. Subtle differences in gene sequences can have a significant impact on the function of protein. Comparing the gene sequences of transaminases from different species has a certain enlightening effect on the study of transaminases. The evolutionary laws of different species can be found in the evolution of transaminase genes. The BCAT protein sequences are downloaded from National Center for Biotechnology International. These files are downloaded in FASTA format. Transaminase sequences of different species obtained by NCBI were introduced through molecular evolutionary genetic analysis (MEGA) software. The Clustal algorithm is used for sequence alignment and the Neighbor joining method to build evolutionary trees (Saitou and Nei, 1987; Sievers and Higgins, 2021). Evolutionary trees infer their kinship based on the similarity of gene sequences, with closer branches meaning closer relatives, higher sequence similarities, and closer cumulative branch lengths indicating closer kinship (as shown in Figure 3).
FIGURE 3. Mega11 maps the BCAT gene phylogenetic tree. The sequences for all species are from NCBI. Homo sapiens (NP_001171562.1), Escherichia coli str. K-12substr.MG1655(YP_026247.1), A. thaliana (NP_001320930.1), Caenorhabditis elegans (NP_510144.1), M. tuberculosis H37Rv (NP_216726.1), S. cerevisiae S288C(NP_012078.3), Schizosaccharomyces pombe (NP_595180.2), Hordeum vulgare subsp. vulgare (XP_5.044979232), Triticum aestivum (XP_044377163.1), Danio rerio (NP_956358.1), Cucumis melo (XP_008444507.1), Mannheimia sp. USDA-ARS-USMARC-1261 (AHG72724.1), Streptococcus pneumoniae (QUY39052.1), Staphylococcus aureus subsp. aureus ST228(CCJ14319.1), Pseudomonas aeruginosa BL05 (ERY42690.1), Xenopus laevis (XP_018106594.1), Ovis aries (NP_001009444.1), Bos taurus (NP_001077113.1), Solanum tuberosum (NP_001275385.1). The numbers represent the bootstrap values (in percentage) for each branch point.
3 BCAT gene expression and function in plants
BCAT1 in plants was recently studied in wheat (Triticum aestivum), where it was found that BCAT can regulate susceptibility to wheat rust (Corredor-Moreno et al., 2021). BCAA aminotransferase (known as TaBCAT1) was found in pathogen-infected bread wheat as a positive regulator of wheat rust sensitivity. Destruction of TaBCAT1 inhibited the infection of yellow rust and stem rust and increased levels of BCAA in TaBCAT1-destroyed mutants that regulated BCAA metabolism in wheat. TaBCAT1 mutants also showed elevated levels of salicylic acid and enhanced expression of related defense genes. There is a correlation between BCAA levels in wheat and yellow rust, highlighting the role of BCAT in plant defense responses. Disrupting TaBCAT1 inhibits wheat infection by the wheat yellow and stem rust fungi, considering the crucial role of TaBCAT1 in pathogen invasion, may be a target for manipulation to increase resistance to pathogen infection. The BCAT gene isolated in H. vulgare is regulated by drought stress. The transcription level of Hvbcat-1 increases under drought stress, and degradation of BCAAs can serve as a detoxification mechanism to keep free branched-chain amino acids at low or non-toxic levels (Malatrasi et al., 2006). BCAT can also improve the drought tolerance of rice (Oryza sativa), identifying cytosolic BCAT1 as a candidate gene for plant drought tolerance enhancement and participating in the accumulation of drought-stress-mediated BCAAs in rice (Shim et al., 2023). Overexpression of OsDAT under drought conditions in paddy fields increases cereal yields. Melon BCAT1 gene was expressed in Escherichia coli, showing branched-chain amino acid transaminase activity. The expression of BCAT1 is low in vegetative tissues, but during fruit ripening, expression in pulp and peel tissues increases. Ripe fruits of aromatic varieties generally show high expression of BCAT1 compared to unripe fruits (Gonda et al., 2010). In tomatoes, the effects of monoisoform BCAT on fruits were studied. They found ketoacids rather than amino acids to be possible precursors of branched-chain flavor volatiles. The change in expression level of BCAT isoforms did not affect the synthesis of branched-chain volatiles, indicating that BCAT was not a suitable target for metabolic engineering of important flavor compounds (Kochevenko et al., 2012). It was found that the increase of BCAT gene expression induced by low temperature stress could promote the synthesis of Leu in tomato fruit (Zhang W. F. et al., 2019). BCAT is also potentially involved in drought-resistant pathways in Arabidopsis, where BCAT2 is a pathogenic gene with naturally variable BCAA content (Angelovici et al., 2013). BCATs are essential for the free growth of betarhizobia and their ability to form effective symbionts with host plant of the Mimosa genus (Chen et al., 2012). Plants have different levels of gene expression in different environments. The development of genome transcriptome sequencing has helped to understand plant defense responses in different environments and plant susceptibility to disease. A deeper understanding of BCAT will provide better protection for cash crops from pathogens and harsh environmental stresses.
4 BCAT gene expression and function in animals
Recent studies of BCAT1 in animals were conducted in mouse embryonic stem cells (Chen et al., 2020). Regulation of self-renewal and pluripotency of mouse embryonic stem cells is done by Ras signaling. High-throughput sequencing of undifferentiated mouse pluripotent stem cells as well as differentiated cells revealed that BCAT1 is highly expressed in mouse embryonic stem cells and is significantly downregulated in differentiated cells. The BCAT1 gene in mouse embryonic stem cells was knocked out with CRISPR-cas9, which led to spontaneous differentiation of mouse embryonic stem cells. The specific mechanism of self-differentiation of mouse embryonic stem cells needs to be further studied. Genome-wide bisulfite sequencing (WGBS) analysis showed that BCAT1-knockout cells had reduced levels of DNA methylation on each chromosome throughout the genome, altering gene expression in multiple pathways. Further research into the function of BCAT1 in mouse embryonic stem cell (ESC) and the analysis of its underlying mechanisms is needed. BCAA aminotransferases (BCAT1/ECA39) are also involved in apoptosis. Overexpression of BCAT1/ECA39 in murine cells had no significant effect on the proliferation of cells grown at high serum concentrations, but cell viability decreased under conditions of serum deprivation (Eden and Benvenisty, 1999). Mice with deletion of mitochondrial branched-chain aminotransferase (BCATm) (expressed in muscle and brain glial cells) showed a significant increase in BCAAs. Loss of BCAA transamination leads to changes in dietary choices and hypothalamic neuropeptide gene expression (Purpera et al., 2012). The expression of the BCAT2 gene is regulated during mouse adipocyte differentiation and is affected by the level of nutrients (Kitsy et al., 2014). Alzheimer’s disease (AD) is a chronic neurodegenerative disease and the expression of BCAT1 was significantly reduced in mice with this disease (Li et al., 2018).
The nonsense mutation in the mouse BCAT2 gene can lead to BCAA catabolic defects and high levels of BCAAs accumulation in plasma and urine, the direct proarrhythmic effect of elevated BCAAs levels, and the mTOR pathway can eliminate the proarrhythmic effect caused by elevated BCAAs (Portero et al., 2022). BCAA catabolic defects lead to the accumulation of BCKAs in myocardia. BCKAs may promote heart failure by inhibiting the respiratory chain and increasing the superoxide production of mitochondria. On the contrary, enhancing the activity of branch-chain α-ketoate dehydrogenase can significantly reduce cardiac dysfunction after pressure overload (Sun et al., 2016). Mice with BCAT2 exon 4-6 targeting deletion showed lower body weight and exercise intolerance. BCAT1 inhibitors alleviate childhood asthma in mice by affecting airway remodeling and autophagy. BCAT1 is upregulated in chronic airway disease; however, its role in childhood asthma is unclear. BCAT1 is upregulated in mice with neonatal asthma, and BCAT1 inhibitors may inhibit airway inflammation and remodeling by reducing autophagy, which may provide a new therapeutic direction for childhood asthma (Li et al., 2022).
Celetodes parasitizing plants and animals have also been studied on BCAT1 (Mansfeld et al., 2015). Impaired BCAT1 gene expression in nematodes leads to increased lifespan and increased BCAA levels. Overexpression of BCAT1 impairs longevity and fecundity, and the transcription factor HLH-15 controls and effectively co-regulates physiological ageing with BCAT1. Consistent with the findings in rodents, supplementation with BCAAs extended the lifespan of nematodes. BCAAs act as peripherally derived metabolic factors that induce central nervous system endocrine responses that ultimately lead to a prolonged healthy range. Polymorphisms in the BCAT1 gene also have a protective effect against acute coronary syndrome (Ramírez-Bello et al., 2020). BCAT1 redox function maintains cell mitosis, which is essential for chromosome separation, and provides an explanation for BCAT1’s role in promoting cancer cell proliferation (Francois et al., 2022).
5 BCAT gene expression and function in microorganisms
BCAT in microorganisms has been widely studied, but BCAT purification has been less reported, and BCATs can be purified by column chromatography in Helicobacter pylori (Saito et al., 2007). Bacterial and archaeal BCAT is distinguished from eukaryotes by broad substrate specificity (Bezsudnova et al., 2017). Hyperthermophilic archaea exhibit high specificity for BCAAs and their ketone analogues (Bezsudnova et al., 2016). BCAT has been used in the biosynthesis of unnatural amino acids. Aminotransferases are important biocatalysts for the synthesis of chiral amines, have the ability to introduce amino groups into ketones or ketoacids, and have high enantioselectivity (Zheng et al., 2019). Most of them are introduced as branched-chain amino acids inserted into E. coli for clonal expression and purification (Stekhanova et al., 2017). E. coli BCAT can be used to synthesize some asymmetric unnatural amino acids (Yu et al., 2014), such as L-n-Leucine, L-n-Valine, and L-Neopentylglycine. The expression of BCAT in E. coli is associated with the production of pantothenic acid in industry (Zhang B. et al., 2019). It is expressed in E. coli by cloning BCAT from Pseudomonas (PsBCAT). PsBCAT shows a relatively wide substrate spectrum and exhibits significant activity against a large number of aliphatic L-amino acids. In addition, PsBCAT demonstrates activity with aromatic L-amino acids, such as L-histidine and L-threonine. The BCAT sequences of Bacillus subtilis, Corynebacterium glutamate, and Pseudomonas showed varying degrees of similarity with E. coli, respectively. BCAT protein is mainly produced in the form of a soluble protein, and the expression of PsBCAT is preferred over other BCATs and is more selective for substrates. So it is more likely to be widely used in industry.
The BCAT, encoded by the ilvE gene, is involved in acid tolerance of Streptococcus mutans, which is considered a pathogen of human dental caries and affects dental health as well as oral microbial survival. Under acid-stressed conditions, ilvE genes are upregulated in Streptococcus mutans, and growth lags in Streptococcus mutans ilvE mutant strains when nutrition restricts branched-chain amino acids (Santiago et al., 2012). In staphylococci, ilvE mutants were shown to lose enzymatic activity against BCAAs, demonstrating their role in amino acid catabolism (Madsen et al., 2002). Mutant strains of Staphylococcus carnosus lacking BCAT activity are unable to produce suitable branched-chain α ketoacid precursors for branched-chain fatty acid biosynthesis and need to be grown in medium containing 2-methylpropionic acid (Beck, 2005). Mycobacterium BCATs are key enzymes for the synthesis of methionine, and blocking methionine biosynthesis in mycobacteria can inhibit the growth of mycobacteria (Pham et al., 2022). In contrast to higher fungi, the biosynthetic genes of the oil-producing fungus Mortierella alpina BCAAs are virtually immune to transcriptional regulation, indicating a sustained production of BCAAs (Sonnabend et al., 2022). Isolation of Lactobacillus fermentum YZU-06 with high utilization rate of branched-chain amino acids in Jinhua ham is a promising starter culture that can improve the flavor of fermented meat products (Liu et al., 2022a). Moreover, the addition of Leu and the mixed starter of L. fermentum YZU-06 and S. saprophyticus CGMCC 3475 could produce methyl branched-chain aldehyde and improve the overall quality of fermented sausages (Liu et al., 2022b). S. cerevisiae BCATs are not only involved in the production of BCAAs but are also associated with the production of fusels as a precursor to volatile flavor components of next-generation biofuels or as fermentation products. The overexpression of these BCATs also increases the industrial production of fusel alcohols (Eden et al., 1996). Mitochondrial Bat1 in S. cerevisiae regulates Val biosynthesis, but Bat2 has little effect on Val biosynthesis. Whether the biosynthesis of Leuand Ile is mainly regulated by Bat1 or Bat2, or by both enzymes, has not been clearly explained. S. cerevisiae may also contain more than these two aminotransferases, which may be regulated by other undiscovered aminotransferases (Takpho et al., 2018).
Pathogens rely on host amino acids to grow and survive, BCATs regulate the metabolism of BCAAs, and BCAAs are essential for the growth of various microorganisms. Targeting BCATs may disrupt pathogen utilization of BCAAs, impairing their ability to reproduce. The development of BCAT inhibitors as potential antimicrobials can selectively block BCAT activity, such as Aminooxy compounds being detected as potential BCAT inhibitors, hindering pathogen utilization of BCAAs for growth and survival (Venos et al., 2004), but further research is needed to elucidate the specific mechanisms by which BCATs promote pathogen growth.
6 BCAAs aminotransferases and human diseases
BCATs are closely related to diabetes. Plasma BCAAs are significantly elevated in patients with type 1 diabetes mellitus (Karusheva et al., 2021), the decrease in glycolysis reduces the content of amino receptors (α-ketoglutarate, pyruvate, and oxaloacetate), the branched-chain amino acid transamination reaction is reduced, and the level of branched-chain amino acids in human plasma will be significantly increased, and the flux of BCAAs through BCKAD is impaired due to excess NADH and an increase in the ratio of acyl-CoA to CoA-SH (Holeček, 2020). In addition, BCAT1 methylation was found to be associated with obesity (Kaufman et al., 2018), elevated plasma BCAAs for obesity states (She et al., 2007), BCAT1 as a candidate gene associated with obesity (Chen et al., 2013), and obesity associated with type 2 diabetes (Nadler et al., 2000). BCAT1 single nucleotide polymorphisms were identified as associated with type 2 diabetes from a genome-wide association scans (Rampersaud et al., 2007), and in the skeletal muscle of patients with type 2 diabetes, the expression of the gene encoding the first step enzyme involved in BCAA metabolism (BCAT2) is reduced, and the patient’s branched-chain amino acid metabolism is inhibited. Glucose load further attenuates BCAA catabolism in patients with type 2 diabetes, and circulating plasma BCAA levels change. However, the transcriptome regulatory mechanisms of genes involved in BCAA catabolism are unknown (Sjögren et al., 2021).
BCATs are mainly expressed in the brain and neurons, and BCATs are involved in N shuttles between astrocytes and neurons in the brain, BCATs are closely related to brain diseases as well as neurological diseases (Knerr et al., 2019). Maple syrup urine disease (MSUD) is an inherited metabolic disorder, BCKD complex subunit mutations lead to the accumulation of BCKAs, the exact molecular mechanism by which BCKAs cause neuronal damage in MSUD is not fully understood, studies indicate that the accumulation of BCKAs disrupts mitochondrial function, induces oxidative stress, and impairs neurotransmitter synthesis and release (Funchal et al., 2006). Mitochondrial BCAT2 mutations in N-ethyl-N-nitrosourea-treated mices produce pathological features similar to MSUD, providing an animal model for studying the metabolism of BCAAs (Wu et al., 2004), unlike MSUD, elevated plasma BCAAs in patients with BCAT2 deficiency do not lead to acute encephalopathy (Knerr et al., 2019). Secondly, according to a study of Alzheimer’s patients, high levels of serum BCAA, glutamate, and BCAT were positively correlated with AD severity. Glutamate production is increased by elevated BCAT activity, which may deteriorate brain function and be associated with impaired cognitive function and faster cognitive decline (Hudd et al., 2019). BCATs participate in regulating the levels of neurotransmitters such as glutamate and γ-aminobutyric acid. BCAT inhibition may lead to an imbalance in neurotransmitter levels, leading to neurological diseases and neuronal dysfunction. The molecular mechanisms underlying BCAT dysfunction leading to these diseases include impaired neurotransmitter synthesis, mitochondrial dysfunction, and oxidative stress (Funchal et al., 2006). In the brains of patients with vascular dementia (VaD) and dementia with Lewy bodies (DLB), hBCATm protein expression was significantly increased, similar to that reported in AD brains (Ashby et al., 2017). Associated with Pap syndrome, a metabolic neuromuscular disease, overexpression of the BCAT gene can rescue the growth of cells lacking the phosphatidyltransferase TAZ1 gene (Antunes et al., 2019), The main contribution of BCATs may be the compensatory increase in TCA circulating flux, but the specific mechanism of the overexpression of the BCAT gene to rescue the growth of cells lacking the phosphatidyltransferase TAZ1 gene is unclear.
Overexpression of BCAT1 in leukaemia stem cells reduces intracellular α-ketoglutarate (αKG), and DNA demethylase inactivation leads to DNA hypermethylation (Raffel et al., 2017). BCAT1 regulates gene epigenetics by restricting intracellular αKG to stabilize the HIF1α protein required for the maintenance of leukemia stem cells (Raffel et al., 2017). In chronic myeloid leukaemia (CML), BCAT1 promotes clonal growth by forming BCAAs from amino groups of BCKAs. Conversely, reducing the expression of BCAT1 promotes cell differentiation and prevents the spread of CML in vivo (Hattori et al., 2017). BCAT has also been studied in cardiovascular diseases. BCAA aminotransferase 1-23C/G polymorphisms have been found to have a protective effect against acute coronary syndrome, but the specific mechanism has not been studied (Ramírez-Bello et al., 2020). Activation of BCAT1 and inhibition of oxoeicosanoid receptor can reduce acute myocardial infarction (Lai et al., 2021). Activation of BCAT1 can also reduce acute myocardial infarction; overexpression of BCAT in the heart can improve myocardial ischemic injury; and targeted treatment of BCAT is a promising strategy for acute myocardial infarction for clinical treatment (Lai et al., 2021). Increased BCAT activity in combination with the branched-chain α-ketoacid dehydrogenase (BCKD) kinase inhibitor BT2, which reduces cardiac BCAA levels, increased forward transamination rates and increased the therapeutic benefit of BCAAs (Voronova et al., 2022).
Most research on BCAT is related to cancer (details are shown in Table 3). BCAT1 shows different activities in cancer, correlated with tumor aggressiveness (Tönjes et al., 2013). BCAT1 is upregulated in isocitrate dehydrogenase (IDH) wildtype but not mutant glioblastoma multiforme (GBM) (Tönjes et al., 2013). The BCAT1 inhibitors gabapentin and α-ketoglutaric acid (αKG) kill wild-type IDH GBM cells. The principle is that the inhibition of BCAT1 increases the NAD+/NADH ratio with BCAT1 deletion, impairing oxidative phosphorylation, mTORC1 activity, and nucleotide biosynthesis, leading to mitochondrial dysfunction and loss of ATP, nucleotides, and proteins. (Zhang B. et al., 2022). The hypermethylation of the BCAT1 promoter inhibits the BCAT1 gene, and the decrease in the expression of BCAT1 reduces the supply of glutamate, increases the dependence on glutaminase, and reduces tumor proliferation and invasion (Yi et al., 2021). High expression of BCAT1 is a marker for predicting poor prognosis in IDH1 wild-type glioma patients, providing an important target site for glioblastoma patients (Yi et al., 2021; Huang W. et al., 2022). Noncoding RNAs have been widely studied in recent years, glioblastoma is also regulated by competitive endogenous RNA, circVPS18 accelerates the progression of glioblastoma through miR-1229-3p/BCAT1, providing a potential therapeutic target for glioblastoma (Huang Q. et al., 2022).
Expression and methylation of the BCAT1 gene are associated with human nonalcoholic fatty liver disease. BCAT1 may identify patients at risk for a poor prognosis (Wegermann et al., 2018). Tumors in patients with liver cancer (HCC) show abnormally high expression of the BCAT gene but low expression of BCKD and downstream catabolic enzymes (Ericksen et al., 2019). BCAT1 promotes HCC cell development and metastasis by activating the AKT signaling pathway and epithelial-mesenchymal transformation (EMT) (Ding et al., 2023). High concentrations of gabapentin can inhibit cell proliferation without affecting BCAT1 (Grankvist et al., 2018). BCATc inhibitor 2 is an inhibitor of cytosolic BCAT, which can be synthesized by binding 2-CF3-phenyls to coumarin derivatives (Lu et al., 2022). The cytosolic branched-chain amino acid aminotransferase inhibitor BCATc Inhibitor 2, which protects oleic acid-induced lipid accumulation and apoptosis, is a promising candidate for the treatment of Non-alcoholic fatty liver disease (Lu et al., 2022). Elevated BCAA levels promote excessive activation of mTOR signaling to promote tumor growth. Decreased levels of BCAAs in hepatoma cell culture medium reduce the proliferation rate of hepatoma cells (Ericksen et al., 2019). High expression of BCAT1 and BCKD genes in breast cancer activates mTOR signaling, and BCAA catabolism is enhanced. BCAT1 knockdown may help reduce mTOR signaling and reduce the growth rate of breast cancer cell lines (Zhang and Han, 2017). These studies have found a major role in tumor proliferation. In addition, in the presence of cachexia disease in cancer patients, supplementation with BCAAs improves quality of life due to their anabolic effects and subsequently increases the effectiveness of chemotherapy interventions (Laviano et al., 2005). The tumor diameter in the high-expression group was higher than that in the low-expression group, and the 5-year survival rate was lower in the high-expression group. The high expression of BCAT1 was positively correlated with tumor diameter, lymphatic metastasis, and a poor prognosis. BCAT1 is a potential biological target for breast cancer (Laviano et al., 2005). Another study was to silence the BCAT2 gene in primary cells of the breast cancer cell line MCF-7 and breast tumor to reduce cell proliferation, but the detailed mechanism needs further investigation (Antanavičiūtė et al., 2017). Spectrophotometry and hyperpolarized 13C magnetic resonance spectroscopy (MRS) determined BCAT enzyme activity in vitro for prostate cancer of various origins (humans, mice). Low levels of BCAT activity were present in all prostate cancer models. And BCAT levels were elevated in healthy human prostate tissue relative to malignant tissue (Billingsley et al., 2014). N6-methyladenosine (m6A) RNA methylation plays an important role in tumorigenesis and metastasis, BCAT1 was screened for m6A RNA methylation-related gene in pancreatic cancer, which may be a new therapeutic target, but detailed mechanistic studies have yet to be discovered (Geng et al., 2020). BCAT1 is abnormally expressed in colorectal cancer (CRC) with significantly higher levels of cyclic tumor DNA (ctDNA) methylation, which can be used for CRC diagnosis with high sensitivity and specificity (Xu et al., 2021). Moreover, it was found that long non-coding RNA (lncRNA) TMPO-AS1 can upregulate the expression of BCAT1 through miR-98-5p, thereby promoting the progression of colorectal cancer cells (Ye et al., 2022). BCAT2 protein levels were significantly elevated in human pancreatic ductal adenocarcinoma (PDAC) cells, and BCAT2 knock down significantly inhibited the proliferation of PDAC cells. BCAT2 knockdown significantly inhibited the proliferation of PDAC cells, but untransformed human pancreatic ductal HPDE cells did not, and reduced cellular fatty acid levels were associated with lipid synthesis (Lee et al., 2019). Acetylating lysine 44 (K44), an evolutionarily relatively conserved residue located at the N-terminus of BCAT2, of BCAT2 promotes BCAT2 degradation and inhibits BCAA catabolism and pancreatic cancer growth (Lei et al., 2020). Therefore, BCAT2 may also provide a new therapeutic target for pancreatic cancer, presumably use of the modified BGAT may help the treatment of cancer. In addition, dysregulation of BCAT2 correlates with the overall survival time of gastric cancer patients, and this study contributes to the potential treatment of gastric cancer (Zhang Y. et al., 2022). BCAT1 was found to be a potential therapeutic target for clinical treatment of lung diseases. BCAT1 is overexpressed in human non-small cell lung cancer, and BCAT1 promotes cell proliferation and invasion by regulating the Wnt signaling pathway (Lin et al., 2020). In addition, abnormalities in smooth muscle cells of the pulmonary artery are associated with autophagy, and BCAT1 binds to IRE1 in the endoplasmic reticulum to activate the expression of its downstream pathway XBP-1-RIDD axis, thereby activating autophagy. The RNA-binding protein zinc finger protein 423 promotes autophagy by binding to BCAT1mRNA 3′-untranslated regions (Xin et al., 2020).
BCAT2 can also be used to predict cancer cell responsiveness to ferroptosis-inducing therapies and be used as a sensitive biomarker to evaluate drug response in preclinical cancer models (Wang et al., 2021). BCAT2 plays a crucial role in ferroptosis. Ferroptosis inducers (erastin, sorafenib, and sulfazazine) activate the AMPK/SREBP1 signaling pathway through iron-dependent ferritinophagy, inhibiting BCAT2 transcription (Wang et al., 2021). The overexpression of BCAT2 in the human pancreatic cancer cell line Aspc-1 and hepatocellular carcinoma cells HepG2 increased intracellular glutamate and glutamate release, increased system Xc− activity, and inhibited ferroptosis. System Xc− is located in the cell membrane and mediates cysteine and glutamate transport (Liu et al., 2021). Inhibition of the expression of the BCAT2 gene by RNA interference, thus blocking system Xc− activity, resulted in ferroptosis in cells. Thus, knockdown of the expression of the BCAT2 gene can partially induce ferroptosis. Therefore, highly specific BCAT2 inhibitors can provide an effective treatment for a subset of cancer patients. Conversely, BCAT1 activity is significantly reduced in ferroptosis-induced mesenchymal stem cells, which downregulate ferroptosis by inhibiting transcription of glutathione peroxidase-4 (GPX4) in mesenchymal stem cells (Hu et al., 2023). In different ferroptosis-induced cells, the activity of branched-chain amino acid aminotransferases of different subtypes is altered, and further research is needed.
BCAT converts BCAA to BCKA, which can be further metabolized by the branched-chain ketoacid dehydrogenase (BCKDH) complex, producing acetyl-CoA and entering the tricarboxylic acid (TCA) cycle, providing an additional source of energy for cancer cells (Mayers and Vander Heiden, 2017). In addition, BCAT plays a role in supporting cancer cell growth and proliferation by promoting the biosynthesis of key molecules required for tumor development, such as activating or inhibiting the mTOR signaling pathway to affect cancer cell multiplication (Wolfson et al., 2016; Zhang and Han, 2017). BCKAs produced by BCAT can serve as precursors for the synthesis of fatty acids, cholesterol and other important metabolites. The BCAT-catalyzed transamination reaction leads to the formation of glutamate, which can be used for the biosynthesis of other non-essential amino acids such as glutamine, or the production of a-ketoglutaric acid by other aminotransferases (Altman et al., 2016), followed by glutamic acid as a precursor to the synthesis of glutathione, a major antioxidant molecule. By promoting glutathione synthesis, BCAT helps cancer cells maintain a favorable intracellular redox environment that supports their survival and proliferation (Godwin et al., 1992).
7 Conclusion
In recent years, in-depth research on BCATs have been carried out, from humans to animals and plants and microorganisms, from BCATs chemical structure to function, from BCAT genes to related pathway studies, and have a clearer understanding of BCATs. Research on microbial BCAT is mainly related to the industrial production of its products. Since BCAAs are essential amino acids for humans and cannot be synthesized by humans, the industrial production of BCAAs is crucial. BCATs are not only involved in the production of BCAAs, but also related to the preparation of fusel alcohols and methyl branched-chain flavor compounds, so BCATs can be used to produce fuels and are widely used in the food industry. The study of BCAT will likely improve productivity as well as reduce costs, such as increased enzyme activity or substrate specificity. Plant BCATs are mostly studied on economic crops (barley, wheat, rice, etc.), and mainly emphasizes the role of BCATs in plant defense response, resistance to pathogen invasion and drought or low temperature stress, in-depth study of BCATs will benefit the cultivation of economic crops and food and fruit yield, and better benefit mankind. BCAT studies in animals are associated with diseases, most of which are caused by disorders of branched-chain amino acid metabolism, such as metabolic disorders, cancer, and neurodegenerative diseases. BCAAs metabolism is regulated by a variety of factors. Hormonal regulation (e.g., insulin, glucagon, and growth factors) can affect transcriptional regulation of BCAA pathway enzymes. In addition, multiple signal modulations such as mTOR signaling, insulin signaling, and AMPK signaling. Enzyme regulation, BCKDC kinase (BCKDK) with protein phosphatase 2Cm (PP2Cm) alters branched-chain α-ketoacid dehydrogenase complex (BCKDC) activity to regulate BCAA catabolism. Non-coding RNAs (miRNA, circRNA, lncRNA) are involved in the post-transcriptional regulation of BCAT. Current research on BCAT has certain limitations, such as measuring enzyme activity in vitro, it is impossible to completely mimic the in vivo environment, and most of the research on diseases only shows its correlation, without in-depth study of molecular mechanisms. In-depth understanding of the relationship between BCAT and its gene expression, and the use of genetic engineering to change its activity may provide more accurate and effective treatment. BCAT is not limited to catalysis, but more importantly, it regulates metabolism in the body. Metabolic disorders will inevitably cause a variety of diseases, and further research on its regulatory mechanism may provide a new direction for disease treatment. Cancer has become the main cause of death in humans, in vitro research on cancer cells is limited, after all, the metabolic pathways of the human body in vivo are complex and interrelated, BCAT is an important prognostic tumor marker, the development of drugs for BCAT, will provide new treatment strategies.
Author contributions
CC: Conception, Draft, Writing, Proofreading. HN: Revision, Proofreading. KC: Conception, Draft, Designing. All authors contributed to the article and approved the submitted version.
Funding
This review was funded by the National Natural Science Foundation of China (31861143051 and 31872425).
Acknowledgments
The authors would like to thank Dr. Keping Chen (Jiangsu University) for advice on a draft of the manuscript. The authors would also like to thank Hassan for the manuscript revision.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Altman, B. J., Stine, Z. E., and Dang, C. V. (2016). From Krebs to clinic: glutamine metabolism to cancer therapy. Nat. Rev. Cancer 16, 749. doi:10.1038/nrc.2016.114
Amorim Franco, T. M., Favrot, L., Vergnolle, O., and Blanchard, J. S. (2017). Mechanism-based inhibition of the Mycobacterium tuberculosis branched-chain aminotransferase by d- and l-cycloserine. ACS Chem. Biol. 12, 1235–1244. doi:10.1021/acschembio.7b00142
Amorim Franco, T. M., Hegde, S., and Blanchard, J. S. (2016). Chemical mechanism of the branched-chain aminotransferase IlvE from Mycobacterium tuberculosis. Biochemistry 55, 6295–6303. doi:10.1021/acs.biochem.6b00928
Ananieva, E. A., Patel, C. H., Drake, C. H., Powell, J. D., and Hutson, S. M. (2014). Cytosolic branched chain aminotransferase (BCATc) regulates mTORC1 signaling and glycolytic metabolism in CD4+ T cells. J. Biol. Chem. 289, 18793–18804. doi:10.1074/jbc.M114.554113
Ananieva, E. A., and Wilkinson, A. C. (2018). Branched-chain amino acid metabolism in cancer. Curr. Opin. Clin. Nutr. Metab. Care 21, 64–70. doi:10.1097/MCO.0000000000000430
Angelovici, R., Lipka, A. E., Deason, N., Gonzalez-Jorge, S., Lin, H., Cepela, J., et al. (2013). Genome-wide analysis of branched-chain amino acid levels in Arabidopsis seeds. Plant Cell 25, 4827–4843. doi:10.1105/tpc.113.119370
Antanavičiūtė, I., Mikalayeva, V., Ceslevičienė, I., Milašiūtė, G., Skeberdis, V. A., and Bordel, S. (2017). Transcriptional hallmarks of cancer cell lines reveal an emerging role of branched chain amino acid catabolism. Sci. Rep. 7, 7820. doi:10.1038/s41598-017-08329-8
Antunes, D., Chowdhury, A., Aich, A., Saladi, S., Harpaz, N., Stahl, M., et al. (2019). Overexpression of branched-chain amino acid aminotransferases rescues the growth defects of cells lacking the Barth syndrome-related gene TAZ1. J. Mol. Med. Berl. 97, 269–279. doi:10.1007/s00109-018-1728-4
Ashby, E. L., Kierzkowska, M., Hull, J., Kehoe, P. G., Hutson, S. M., and Conway, M. E. (2017). Altered expression of human mitochondrial branched chain aminotransferase in dementia with Lewy bodies and vascular dementia. Neurochem. Res. 42, 306–319. doi:10.1007/s11064-016-1855-7
Beck, H. C. (2005). Branched-chain fatty acid biosynthesis in a branched-chain amino acid aminotransferase mutant of Staphylococcus carnosus. FEMS Microbiol. Lett. 243, 37–44. doi:10.1016/j.femsle.2004.11.041
Bezsudnova, E. Y., Boyko, K. M., and Popov, V. O. (2017). Properties of bacterial and archaeal branched-chain amino acid aminotransferases. Biochem. (Mosc) 82, 1572–1591. doi:10.1134/S0006297917130028
Bezsudnova, E. Y., Stekhanova, T. N., Suplatov, D. A., Mardanov, A. V., Ravin, N. V., and Popov, V. O. (2016). Experimental and computational studies on the unusual substrate specificity of branched-chain amino acid aminotransferase from Thermoproteus uzoniensis. Arch. Biochem. Biophys. 607, 27–36. doi:10.1016/j.abb.2016.08.009
Billingsley, K. L., Park, J. M., Josan, S., Hurd, R., Mayer, D., Spielman-Sun, E., et al. (2014). The feasibility of assessing branched-chain amino acid metabolism in cellular models of prostate cancer with hyperpolarized [1-(13)C]-ketoisocaproate. Magn. Reson Imaging 32, 791–795. doi:10.1016/j.mri.2014.04.015
Cano, N. J., Fouque, D., and Leverve, X. M. (2006). Application of branched-chain amino acids in human pathological states: renal failure. J. Nutr. 136, 299S–307s. doi:10.1093/jn/136.1.299S
Chen, J., Meng, Y., Zhou, J., Zhuo, M., Ling, F., Zhang, Y., et al. (2013). Identifying candidate genes for Type 2 Diabetes Mellitus and obesity through gene expression profiling in multiple tissues or cells. J. Diabetes Res. 2013, 970435. doi:10.1155/2013/970435
Chen, S., Chen, B., Su, G., Chen, J., Guo, D., Yin, Q., et al. (2020). Branched-chain amino acid aminotransferase-1 regulates self-renewal and pluripotency of mouse embryonic stem cells through Ras signaling. Stem Cell Res. 49, 102097. doi:10.1016/j.scr.2020.102097
Chen, W. M., Prell, J., James, E. K., Sheu, D. S., and Sheu, S. Y. (2012). Biosynthesis of branched-chain amino acids is essential for effective symbioses between betarhizobia and Mimosa pudica. Microbiol. Read. 158, 1758–1766. doi:10.1099/mic.0.058370-0
Corredor-Moreno, P., Minter, F., Davey, P. E., Wegel, E., Kular, B., Brett, P., et al. (2021). The branched-chain amino acid aminotransferase TaBCAT1 modulates amino acid metabolism and positively regulates wheat rust susceptibility. Plant Cell 33, 1728–1747. doi:10.1093/plcell/koab049
De Campos-Ferraz, P. L., Andrade, I., Das Neves, W., Hangai, I., Alves, C. R., and Lancha, A. H. (2014). An overview of amines as nutritional supplements to counteract cancer cachexia. J. Cachexia Sarcopenia Muscle 5, 105–110. doi:10.1007/s13539-014-0138-x
Diebold, R., Schuster, J., Däschner, K., and Binder, S. (2002). The branched-chain amino acid transaminase gene family in Arabidopsis encodes plastid and mitochondrial proteins. Plant Physiol. 129, 540–550. doi:10.1104/pp.001602
Dimou, A., Tsimihodimos, V., and Bairaktari, E. (2022). The critical role of the branched chain amino acids (BCAAs) catabolism-regulating enzymes, branched-chain aminotransferase (BCAT) and branched-chain α-keto acid dehydrogenase (BCKD), in human pathophysiology. Int. J. Mol. Sci. 23, 4022. doi:10.3390/ijms23074022
Ding, Y., Wang, X., Lu, S., Lai, A., Xie, B., He, X., et al. (2023). BCAT1, as a prognostic factor for HCC, can promote the development of liver cancer through activation of the AKT signaling pathway and EMT. J. Mol. Histol. 54, 25–39. doi:10.1007/s10735-022-10108-3
Eden, A., and Benvenisty, N. (1999). Involvement of branched-chain amino acid aminotransferase (Bcat1/Eca39) in apoptosis. FEBS Lett. 457, 255–261. doi:10.1016/s0014-5793(99)01054-6
Eden, A., Simchen, G., and Benvenisty, N. (1996). Two yeast homologs of ECA39, a target for c-Myc regulation, code for cytosolic and mitochondrial branched-chain amino acid aminotransferases. J. Biol. Chem. 271, 20242–20245. doi:10.1074/jbc.271.34.20242
Ericksen, R. E., Lim, S. L., Mcdonnell, E., Shuen, W. H., Vadiveloo, M., White, P. J., et al. (2019). Loss of BCAA catabolism during carcinogenesis enhances mTORC1 activity and promotes tumor development and progression. Cell Metab. 29, 1151–1165. doi:10.1016/j.cmet.2018.12.020
Espinosa-Cantú, A., Ascencio, D., Herrera-Basurto, S., Xu, J., Roguev, A., Krogan, N. J., et al. (2018). Protein moonlighting revealed by noncatalytic phenotypes of yeast enzymes. Genetics 208, 419–431. doi:10.1534/genetics.117.300377
Francois, L., Boskovic, P., Knerr, J., He, W., Sigismondo, G., Schwan, C., et al. (2022). BCAT1 redox function maintains mitotic fidelity. Cell Rep. 41, 111524. doi:10.1016/j.celrep.2022.111524
Funchal, C., Latini, A., Jacques-Silva, M. C., Dos Santos, A. Q., Buzin, L., Gottfried, C., et al. (2006). Morphological alterations and induction of oxidative stress in glial cells caused by the branched-chain alpha-keto acids accumulating in maple syrup urine disease. Neurochem. Int. 49, 640–650. doi:10.1016/j.neuint.2006.05.007
Geng, Y., Guan, R., Hong, W., Huang, B., Liu, P., Guo, X., et al. (2020). Identification of m6A-related genes and m6A RNA methylation regulators in pancreatic cancer and their association with survival. Ann. Transl. Med. 8, 387. doi:10.21037/atm.2020.03.98
Godwin, A. K., Meister, A., O'dwyer, P. J., Huang, C. S., Hamilton, T. C., and Anderson, M. E. (1992). High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. U. S. A. 89, 3070–3074. doi:10.1073/pnas.89.7.3070
Gonda, I., Bar, E., Portnoy, V., Lev, S., Burger, J., Schaffer, A. A., et al. (2010). Branched-chain and aromatic amino acid catabolism into aroma volatiles in Cucumis melo L. fruit. J. Exp. Bot. 61, 1111–1123. doi:10.1093/jxb/erp390
Goto, M., Miyahara, I., Hayashi, H., Kagamiyama, H., and Hirotsu, K. (2003). Crystal structures of branched-chain amino acid aminotransferase complexed with glutamate and glutarate: true reaction intermediate and double substrate recognition of the enzyme. Biochemistry 42, 3725–3733. doi:10.1021/bi026722f
Grankvist, N., Lagerborg, K. A., Jain, M., and Nilsson, R. (2018). Gabapentin can suppress cell proliferation independent of the cytosolic branched-chain amino acid transferase 1 (BCAT1). Biochemistry 57, 6762–6766. doi:10.1021/acs.biochem.8b01031
Hattori, A., Tsunoda, M., Konuma, T., Kobayashi, M., Nagy, T., Glushka, J., et al. (2017). Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia. Nature 545, 500–504. doi:10.1038/nature22314
Holeček, M. (2018). Branched-chain amino acids in health and disease: metabolism, alterations in blood plasma, and as supplements. Nutr. Metab. (Lond) 15, 33. doi:10.1186/s12986-018-0271-1
Holeček, M. (2020). Why are branched-chain amino acids increased in starvation and diabetes? Nutrients 12, 3087. doi:10.3390/nu12103087
Hu, G., Cui, Z., Chen, X., Sun, F., Li, T., Li, C., et al. (2023). Suppressing mesenchymal stromal cell ferroptosis via targeting a metabolism-epigenetics Axis corrects their poor retention and insufficient healing benefits in the injured liver milieu. Adv. Sci. (Weinh) 10, e2206439. doi:10.1002/advs.202206439
Huang, Q., Li, W., Huang, Y., Chen, Q., and Wei, W. (2022a). Circular RNA VPS18 promotes glioblastoma progression by regulating miR-1229-3p/BCAT1 Axis. Neurotox. Res. 40, 1138–1151. doi:10.1007/s12640-022-00530-6
Huang, W., Hao, Z., Mao, F., and Guo, D. (2022b). Small molecule inhibitors in adult high-grade glioma: from the past to the future. Front. Oncol. 12, 911876. doi:10.3389/fonc.2022.911876
Hudd, F., Shiel, A., Harris, M., Bowdler, P., Mccann, B., Tsivos, D., et al. (2019). Novel blood biomarkers that correlate with cognitive performance and hippocampal volumetry: potential for early diagnosis of Alzheimer's disease. J. Alzheimers Dis. 67, 931–947. doi:10.3233/JAD-180879
Hutson, S. M., Sweatt, A. J., and Lanoue, K. F. (2005). Branched-chain [corrected] amino acid metabolism: implications for establishing safe intakes. J. Nutr. 135, 1557S–64s. doi:10.1093/jn/135.6.1557S
Inoue, K., Kuramitsu, S., Aki, K., Watanabe, Y., Takagi, T., Nishigai, M., et al. (1988). Branched-chain amino acid aminotransferase of Escherichia coli: overproduction and properties. J. Biochem. 104, 777–784. doi:10.1093/oxfordjournals.jbchem.a122549
Islam, M. M., Nautiyal, M., Wynn, R. M., Mobley, J. A., Chuang, D. T., and Hutson, S. M. (2010). Branched-chain amino acid metabolon: interaction of glutamate dehydrogenase with the mitochondrial branched-chain aminotransferase (BCATm). J. Biol. Chem. 285, 265–276. doi:10.1074/jbc.M109.048777
Karusheva, Y., Strassburger, K., Markgraf, D. F., Zaharia, O. P., Bódis, K., Kössler, T., et al. (2021). Branched-chain amino acids associate negatively with postprandial insulin secretion in recent-onset diabetes. J. Endocr. Soc. 5, bvab067. doi:10.1210/jendso/bvab067
Kaufman, J., Montalvo-Ortiz, J. L., Holbrook, H., O'loughlin, K., Orr, C., Kearney, C., et al. (2018). Adverse childhood experiences, epigenetic measures, and obesity in youth. J. Pediatr. 202, 150–156. doi:10.1016/j.jpeds.2018.06.051
Kido, R. (1988). Pancreatic branched-chain-amino-acid aminotransferase. Methods Enzymol. 166, 275–281. doi:10.1016/s0076-6879(88)66037-x
Kingsbury, J. M., Sen, N. D., and Cardenas, M. E. (2015). Branched-chain aminotransferases control TORC1 signaling in Saccharomyces cerevisiae. PLoS Genet. 11, e1005714. doi:10.1371/journal.pgen.1005714
Kispal, G., Steiner, H., Court, D. A., Rolinski, B., and Lill, R. (1996). Mitochondrial and cytosolic branched-chain amino acid transaminases from yeast, homologs of the myc oncogene-regulated Eca39 protein. J. Biol. Chem. 271, 24458–24464. doi:10.1074/jbc.271.40.24458
Kitsy, A., Carney, S., Vivar, J. C., Knight, M. S., Pointer, M. A., Gwathmey, J. K., et al. (2014). Effects of leucine supplementation and serum withdrawal on branched-chain amino acid pathway gene and protein expression in mouse adipocytes. PLoS One 9, e102615. doi:10.1371/journal.pone.0102615
Knerr, I., Colombo, R., Urquhart, J., Morais, A., Merinero, B., Oyarzabal, A., et al. (2019). Expanding the genetic and phenotypic spectrum of branched-chain amino acid transferase 2 deficiency. J. Inherit. Metab. Dis. 42, 809–817. doi:10.1002/jimd.12135
Kochevenko, A., Araújo, W. L., Maloney, G. S., Tieman, D. M., Do, P. T., Taylor, M. G., et al. (2012). Catabolism of branched chain amino acids supports respiration but not volatile synthesis in tomato fruits. Mol. Plant 5, 366–375. doi:10.1093/mp/ssr108
Lai, Q., Yuan, G., Shen, L., Zhang, L., Fu, F., Liu, Z., et al. (2021). Oxoeicosanoid receptor inhibition alleviates acute myocardial infarction through activation of BCAT1. Basic Res. Cardiol. 116, 3. doi:10.1007/s00395-021-00844-0
Laviano, A., Muscaritoli, M., Cascino, A., Preziosa, I., Inui, A., Mantovani, G., et al. (2005). Branched-chain amino acids: the best compromise to achieve anabolism? Curr. Opin. Clin. Nutr. Metab. Care 8, 408–414. doi:10.1097/01.mco.0000172581.79266.19
Lee, J. H., Cho, Y. R., Kim, J. H., Kim, J., Nam, H. Y., Kim, S. W., et al. (2019). Branched-chain amino acids sustain pancreatic cancer growth by regulating lipid metabolism. Exp. Mol. Med. 51, 1–11. doi:10.1038/s12276-019-0350-z
Lee-Peng, F. C., Hermodson, M. A., and Kohlhaw, G. B. (1979). Transaminase B from Escherichia coli: quaternary structure, amino-terminal sequence, substrate specificity, and absence of a separate valine-alpha-ketoglutarate activity. J. Bacteriol. 139, 339–345. doi:10.1128/JB.139.2.339-345.1979
Lei, M. Z., Li, X. X., Zhang, Y., Li, J. T., Zhang, F., Wang, Y. P., et al. (2020). Acetylation promotes BCAT2 degradation to suppress BCAA catabolism and pancreatic cancer growth. Signal Transduct. Target Ther. 5, 70. doi:10.1038/s41392-020-0168-0
Li, H., Ye, D., Xie, W., Hua, F., Yang, Y., Wu, J., et al. (2018). Defect of branched-chain amino acid metabolism promotes the development of Alzheimer's disease by targeting the mTOR signaling. Biosci. Rep. 38. doi:10.1042/BSR20180127
Li, J., Chen, M., Lu, L., Wang, J., and Tan, L. (2022). Branched-chain amino acid transaminase 1 inhibition attenuates childhood asthma in mice by effecting airway remodeling and autophagy. Respir. Physiol. Neurobiol. 306, 103961. doi:10.1016/j.resp.2022.103961
Lin, X., Tan, S., Fu, L., and Dong, Q. (2020). BCAT1 overexpression promotes proliferation, invasion, and Wnt signaling in non-small cell lung cancers. Onco Targets Ther. 13, 3583–3594. doi:10.2147/OTT.S237306
Liu, M. R., Zhu, W. T., and Pei, D. S. (2021). System Xc(-): a key regulatory target of ferroptosis in cancer. Invest. New Drugs 39, 1123–1131. doi:10.1007/s10637-021-01070-0
Liu, R., Lu, C., Wang, Y., Shen, Y., Ge, Q., Wu, M., et al. (2022a). Characterization of a lactic acid bacteria using branched-chain amino acid transaminase and protease from Jinhua Ham and application in myofibrillar protein model. Meat Sci. 191, 108852. doi:10.1016/j.meatsci.2022.108852
Liu, R., Ma, Y., Chen, L., Lu, C., Ge, Q., Wu, M., et al. (2022b). Effects of the addition of leucine on flavor and quality of sausage fermented by Lactobacillus fermentum YZU-06 and Staphylococcus saprophyticus CGMCC 3475. Front. Microbiol. 13, 1118907. doi:10.3389/fmicb.2022.1118907
Lu, Z., Sun, G. F., Pan, X. A., Qu, X. H., Yang, P., Chen, Z. P., et al. (2022). BCATc inhibitor 2 ameliorated mitochondrial dysfunction and apoptosis in oleic acid-induced non-alcoholic fatty liver disease model. Front. Pharmacol. 13, 1025551. doi:10.3389/fphar.2022.1025551
Madsen, S. M., Beck, H. C., Ravn, P., Vrang, A., Hansen, A. M., and Israelsen, H. (2002). Cloning and inactivation of a branched-chain-amino-acid aminotransferase gene from Staphylococcus carnosus and characterization of the enzyme. Appl. Environ. Microbiol. 68, 4007–4014. doi:10.1128/aem.68.8.4007-4014.2002
Malatrasi, M., Corradi, M., Svensson, J. T., Close, T. J., Gulli, M., and Marmiroli, N. (2006). A branched-chain amino acid aminotransferase gene isolated from Hordeum vulgare is differentially regulated by drought stress. Theor. Appl. Genet. 113, 965–976. doi:10.1007/s00122-006-0339-6
Maloney, G. S., Kochevenko, A., Tieman, D. M., Tohge, T., Krieger, U., Zamir, D., et al. (2010). Characterization of the branched-chain amino acid aminotransferase enzyme family in tomato. Plant Physiol. 153, 925–936. doi:10.1104/pp.110.154922
Mansfeld, J., Urban, N., Priebe, S., Groth, M., Frahm, C., Hartmann, N., et al. (2015). Branched-chain amino acid catabolism is a conserved regulator of physiological ageing. Nat. Commun. 6, 10043. doi:10.1038/ncomms10043
Mayers, J. R., and Vander Heiden, M. G. (2017). Nature and nurture: what determines tumor metabolic phenotypes? Cancer Res. 77, 3131–3134. doi:10.1158/0008-5472.CAN-17-0165
Nadler, S. T., Stoehr, J. P., Schueler, K. L., Tanimoto, G., Yandell, B. S., and Attie, A. D. (2000). The expression of adipogenic genes is decreased in obesity and diabetes mellitus. Proc. Natl. Acad. Sci. U. S. A. 97, 11371–11376. doi:10.1073/pnas.97.21.11371
Papathanassiu, A. E., Ko, J. H., Imprialou, M., Bagnati, M., Srivastava, P. K., Vu, H. A., et al. (2017). BCAT1 controls metabolic reprogramming in activated human macrophages and is associated with inflammatory diseases. Nat. Commun. 8, 16040. doi:10.1038/ncomms16040
Pham, M. T., Tran, T. T. A., and Zayabaatar, E. (2022). Discovery of inhibitors against mycobacterium branched-chain amino acid aminotransferases through in silico screening and experimental evaluation. Lett. Appl. Microbiol. 75, 942–950. doi:10.1111/lam.13763
Portero, V., Nicol, T., Podliesna, S., Marchal, G. A., Baartscheer, A., Casini, S., et al. (2022). Chronically elevated branched chain amino acid levels are pro-arrhythmic. Cardiovasc Res. 118, 1742–1757. doi:10.1093/cvr/cvab207
Purpera, M. N., Shen, L., Taghavi, M., Münzberg, H., Martin, R. J., Hutson, S. M., et al. (2012). Impaired branched chain amino acid metabolism alters feeding behavior and increases orexigenic neuropeptide expression in the hypothalamus. J. Endocrinol. 212, 85–94. doi:10.1530/JOE-11-0270
Que, Y., Yue, X., Yang, N., Xu, Z., Tang, S., Wang, C., et al. (2020). Leucine biosynthesis is required for infection-related morphogenesis and pathogenicity in the rice blast fungus Magnaporthe oryzae. Curr. Genet. 66, 155–171. doi:10.1007/s00294-019-01009-2
Raffel, S., Falcone, M., Kneisel, N., Hansson, J., Wang, W., Lutz, C., et al. (2017). BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature 551, 384–388. doi:10.1038/nature24294
Ramírez-Bello, J., Vargas-Alarcón, G., Pérez-Méndez, Ó., Martínez-Ríos, M. A., Peña-Duque, M. A., Cardoso-Saldaña, G., et al. (2020). THE branched-chain amino acid transaminase 1 -23c/G polymorphism confers protection against acute coronary syndrome. Rev. Invest. Clin. 72, 19–24. doi:10.24875/RIC.19003133
Rampersaud, E., Damcott, C. M., Fu, M., Shen, H., Mcardle, P., Shi, X., et al. (2007). Identification of novel candidate genes for type 2 diabetes from a genome-wide association scan in the Old Order Amish: evidence for replication from diabetes-related quantitative traits and from independent populations. Diabetes 56, 3053–3062. doi:10.2337/db07-0457
Saito, M., Nishimura, K., Wakabayashi, S., Kurihara, T., and Nagata, Y. (2007). Purification of branched-chain amino acid aminotransferase from Helicobacter pylori NCTC 11637. Amino Acids 33, 445–449. doi:10.1007/s00726-006-0452-5
Saitou, N., and Nei, M. (1987). The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4, 406–425. doi:10.1093/oxfordjournals.molbev.a040454
Santiago, B., Macgilvray, M., Faustoferri, R. C., and Quivey, R. G. (2012). The branched-chain amino acid aminotransferase encoded by ilvE is involved in acid tolerance in Streptococcus mutans. J. Bacteriol. 194, 2010–2019. doi:10.1128/JB.06737-11
Schadewaldt, P. (2000). Determination of branched-chain L-amino-acid aminotransferase activity. Methods Enzymol. 324, 23–32. doi:10.1016/s0076-6879(00)24215-8
Schiroli, D., and Peracchi, A. (2015). A subfamily of PLP-dependent enzymes specialized in handling terminal amines. Biochim. Biophys. Acta 1854, 1200–1211. doi:10.1016/j.bbapap.2015.02.023
She, P., Van Horn, C., Reid, T., Hutson, S. M., Cooney, R. N., and Lynch, C. J. (2007). Obesity-related elevations in plasma leucine are associated with alterations in enzymes involved in branched-chain amino acid metabolism. Am. J. Physiol. Endocrinol. Metab. 293, E1552–E1563. doi:10.1152/ajpendo.00134.2007
Shim, J. S., Jeong, H. I., Bang, S. W., Jung, S. E., Kim, G., Kim, Y. S., et al. (2023). Drought-induced branched-chain amino acid aminotransferase enhances drought tolerance in rice. Plant Physiol. 191, 1435–1447. doi:10.1093/plphys/kiac560
Shimizu, M., Fujii, T., Masuo, S., and Takaya, N. (2010). Mechanism of de novo branched-chain amino acid synthesis as an alternative electron sink in hypoxic Aspergillus nidulans cells. Appl. Environ. Microbiol. 76, 1507–1515. doi:10.1128/AEM.02135-09
Shimomura, Y., Honda, T., Shiraki, M., Murakami, T., Sato, J., Kobayashi, H., et al. (2006). Branched-chain amino acid catabolism in exercise and liver disease. J. Nutr. 136, 250S–3s. doi:10.1093/jn/136.1.250S
Shou, J., Chen, P. J., and Xiao, W. H. (2019). The effects of BCAAs on insulin resistance in athletes. J. Nutr. Sci. Vitaminol. (Tokyo) 65, 383–389. doi:10.3177/jnsv.65.383
Sievers, F., and Higgins, D. G. (2021). The clustal omega multiple alignment package. Methods Mol. Biol. 2231, 3–16. doi:10.1007/978-1-0716-1036-7_1
Sjögren, R. J. O., Rizo-Roca, D., Chibalin, A. V., Chorell, E., Furrer, R., Katayama, S., et al. (2021). Branched-chain amino acid metabolism is regulated by ERRα in primary human myotubes and is further impaired by glucose loading in type 2 diabetes. Diabetologia 64, 2077–2091. doi:10.1007/s00125-021-05481-9
Sonnabend, R., Seiler, L., and Gressler, M. (2022). Regulation of the leucine metabolism in Mortierella alpina. J. Fungi (Basel) 8, 196. doi:10.3390/jof8020196
Stekhanova, T. N., Rakitin, A. L., Mardanov, A. V., Bezsudnova, E. Y., and Popov, V. O. (2017). A Novel highly thermostable branched-chain amino acid aminotransferase from the crenarchaeon Vulcanisaeta moutnovskia. Enzyme Microb. Technol. 96, 127–134. doi:10.1016/j.enzmictec.2016.10.002
Steyer, J. T., Downes, D. J., Hunter, C. C., Migeon, P. A., and Todd, R. B. (2021). Duplication and functional divergence of branched-chain amino acid biosynthesis genes in Aspergillus nidulans. mBio 12, e0076821. doi:10.1128/mBio.00768-21
Sun, H., Olson, K. C., Gao, C., Prosdocimo, D. A., Zhou, M., Wang, Z., et al. (2016). Catabolic defect of branched-chain amino acids promotes heart failure. Circulation 133, 2038–2049. doi:10.1161/CIRCULATIONAHA.115.020226
Takpho, N., Watanabe, D., and Takagi, H. (2018). Valine biosynthesis in Saccharomyces cerevisiae is regulated by the mitochondrial branched-chain amino acid aminotransferase Bat1. Microb. Cell 5, 293–299. doi:10.15698/mic2018.06.637
Tönjes, M., Barbus, S., Park, Y. J., Wang, W., Schlotter, M., Lindroth, A. M., et al. (2013). BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat. Med. 19, 901–908. doi:10.1038/nm.3217
Toyokawa, Y., Koonthongkaew, J., and Takagi, H. (2021). An overview of branched-chain amino acid aminotransferases: functional differences between mitochondrial and cytosolic isozymes in yeast and human. Appl. Microbiol. Biotechnol. 105, 8059–8072. doi:10.1007/s00253-021-11612-4
Tremblay, L. W., and Blanchard, J. S. (2009). The 1.9 A structure of the branched-chain amino-acid transaminase (IlvE) from Mycobacterium tuberculosis. Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun. 65, 1071–1077. doi:10.1107/S1744309109036690
Venos, E. S., Knodel, M. H., Radford, C. L., and Berger, B. J. (2004). Branched-chain amino acid aminotransferase and methionine formation in Mycobacterium tuberculosis. BMC Microbiol. 4, 39. doi:10.1186/1471-2180-4-39
Voronova, V., Sokolov, V., Morias, Y., Boezelman, M. J., Wågberg, M., Henricsson, M., et al. (2022). Evaluation of therapeutic strategies targeting BCAA catabolism using a systems pharmacology model. Front. Pharmacol. 13, 993422. doi:10.3389/fphar.2022.993422
Wang, K., Zhang, Z., Tsai, H. I., Liu, Y., Gao, J., Wang, M., et al. (2021). Branched-chain amino acid aminotransferase 2 regulates ferroptotic cell death in cancer cells. Cell Death Differ. 28, 1222–1236. doi:10.1038/s41418-020-00644-4
Wang, X. L., Li, C. J., Xing, Y., Yang, Y. H., and Jia, J. P. (2015). Hypervalinemia and hyperleucine-isoleucinemia caused by mutations in the branched-chain-amino-acid aminotransferase gene. J. Inherit. Metab. Dis. 38, 855–861. doi:10.1007/s10545-015-9814-z
Wegermann, K., Henao, R., Diehl, A. M., Murphy, S. K., Abdelmalek, M. F., and Moylan, C. A. (2018). Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: a pilot study. PLoS One 13, e0204308. doi:10.1371/journal.pone.0204308
Wolfson, R. L., Chantranupong, L., Saxton, R. A., Shen, K., Scaria, S. M., Cantor, J. R., et al. (2016). Sestrin2 is a leucine sensor for the mTORC1 pathway. Science 351, 43–48. doi:10.1126/science.aab2674
Wu, J. Y., Kao, H. J., Li, S. C., Stevens, R., Hillman, S., Millington, D., et al. (2004). ENU mutagenesis identifies mice with mitochondrial branched-chain aminotransferase deficiency resembling human maple syrup urine disease. J. Clin. Invest. 113, 434–440. doi:10.1172/JCI19574
Xin, W., Zhang, M., Yu, Y., Li, S., Ma, C., Zhang, J., et al. (2020). BCAT1 binds the RNA-binding protein ZNF423 to activate autophagy via the IRE1-XBP-1-RIDD axis in hypoxic PASMCs. Cell Death Dis. 11, 764. doi:10.1038/s41419-020-02930-y
Xu, F., Yu, S., Han, J., Zong, M., Tan, Q., Zeng, X., et al. (2021). Detection of circulating tumor DNA methylation in diagnosis of colorectal cancer. Clin. Transl. Gastroenterol. 12, e00386. doi:10.14309/ctg.0000000000000386
Ye, J., Yan, Y., Xin, L., Liu, J., Tang, T., and Bao, X. (2022). Long non-coding RNA TMPO-AS1 facilitates the progression of colorectal cancer cells via sponging miR-98-5p to upregulate BCAT1 expression. J. Gastroenterol. Hepatol. 37, 144–153. doi:10.1111/jgh.15657
Yi, L., Fan, X., Li, J., Yuan, F., Zhao, J., Nistér, M., et al. (2021). Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas. Aging (Albany NY) 13, 3645–3660. doi:10.18632/aging.202328
Yu, X., Wang, X., and Engel, P. C. (2014). The specificity and kinetic mechanism of branched-chain amino acid aminotransferase from Escherichia coli studied with a new improved coupled assay procedure and the enzyme's potential for biocatalysis. Febs J. 281, 391–400. doi:10.1111/febs.12609
Zhang, B., Peng, H., Zhou, M., Bao, L., Wang, C., Cai, F., et al. (2022a). Targeting BCAT1 combined with α-ketoglutarate triggers metabolic synthetic lethality in glioblastoma. Cancer Res. 82, 2388–2402. doi:10.1158/0008-5472.CAN-21-3868
Zhang, B., Zhang, X. M., Wang, W., Liu, Z. Q., and Zheng, Y. G. (2019a). Metabolic engineering of Escherichia coli for d-pantothenic acid production. Food Chem. 294, 267–275. doi:10.1016/j.foodchem.2019.05.044
Zhang, L., and Han, J. (2017). Branched-chain amino acid transaminase 1 (BCAT1) promotes the growth of breast cancer cells through improving mTOR-mediated mitochondrial biogenesis and function. Biochem. Biophys. Res. Commun. 486, 224–231. doi:10.1016/j.bbrc.2017.02.101
Zhang, W. F., Gong, Z. H., Wu, M. B., Chan, H., Yuan, Y. J., Tang, N., et al. (2019b). Integrative comparative analyses of metabolite and transcript profiles uncovers complex regulatory network in tomato (Solanum lycopersicum L.) fruit undergoing chilling injury. Sci. Rep. 9, 4470. doi:10.1038/s41598-019-41065-9
Zhang, Y., Liu, W., Feng, W., Wang, X., Lei, T., Chen, Z., et al. (2022b). Identification of 14 differentially-expressed metabolism-related genes as potential targets of gastric cancer by integrated proteomics and transcriptomics. Front. Cell Dev. Biol. 10, 816249. doi:10.3389/fcell.2022.816249
Zheng, X., Cui, Y., Li, T., Li, R., Guo, L., Li, D., et al. (2019). Biochemical and structural characterization of a highly active branched-chain amino acid aminotransferase from Pseudomonas sp. for efficient biosynthesis of chiral amino acids. Appl. Microbiol. Biotechnol. 103, 8051–8062. doi:10.1007/s00253-019-10105-9
Keywords: branched-chain amino acid aminotransferases, branched-chain amino acids, evolutionary tree, metabolism, human disease
Citation: Chen C, Naveed H and Chen K (2023) Research progress on branched-chain amino acid aminotransferases. Front. Genet. 14:1233669. doi: 10.3389/fgene.2023.1233669
Received: 09 June 2023; Accepted: 23 October 2023;
Published: 06 November 2023.
Edited by:
Sankar Subramanian, University of the Sunshine Coast, AustraliaReviewed by:
Alexey Goltsov, Moscow State Institute of Radio Engineering, Electronics and Automation, RussiaEul Hyun Suh, University of North Texas Health Science Center, United States
Copyright © 2023 Chen, Naveed and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Keping Chen, kpchen@ujs.edu.cn